https://allsci.com/news/first-in-human-trials/oral-insulin-nanoparticles-endo-axiom-doses-first/ AllScien 2026-09-11T17:29:22.213189Z Endo Axiom takes oral nanoparticle insulin into first-in-human trial https://allsci.com/news/debt-financing/teva-debt-refinancing-refinances-usd-49b-pile-at/ AllScien 2026-09-11T17:17:58.793367Z Teva raises USD 4.9bn to refinance higher-coupon debt https://allsci.com/news/licensing-and-partnerships/imunon-nci-partnership-cancer-with-national/ AllScien 2026-09-11T15:59:10.272768Z IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer https://allsci.com/news/licensing-and-partnerships/dmd-gene-therapy-collaboration-exegenesis-and/ AllScien 2026-09-11T15:36:46.345928Z Exegenesis and Modalis combine muscle-targeting AAV with epigenome editing for preclinical DMD candidate https://allsci.com/news/funding/yarrow-bioscience-funding-graves-disease/ AllScien 2026-09-11T15:31:28.875108Z Yarrow raises USD 150m to advance first-in-class Graves' disease antibody into Phase II https://allsci.com/news/clinical-trials/deep-brain-ultrasound-essential-tremor/ AllScien 2026-09-11T15:23:07.182481Z NeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor https://allsci.com/news/first-in-human-trials/oral-glp-1-peptide-gan-lee-advances-once-weekly/ AllScien 2026-09-11T14:58:08.989378Z Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I https://allsci.com/news/grants/necrotizing-enterocolitis-research-johns-hopkins/ AllScien 2026-09-11T13:56:37.983291Z Johns Hopkins tests pancreatic TLR4–hyperglycemia axis as driver of necrotizing enterocolitis https://allsci.com/news/regulatory/zanzalintinib-fda-approval-extends-exelixis/ AllScien 2026-09-11T13:45:04.918848Z FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027 https://allsci.com/news/clinical-trials/oms1620-clinical-trial-cah-omass-enters-human/ AllScien 2026-09-11T12:52:37.285374Z OMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia https://allsci.com/news/venture-financing/sodium-channel-drugs-epilepsy-navion/ AllScien 2026-09-11T11:52:14.644136Z Navion Neurosciences secures USD 10.8m to pursue sodium-channel drugs for epilepsy and pain https://allsci.com/news/regulatory/pacritinib-vexas-syndrome-fda-grants-fast-track/ AllScien 2026-09-11T11:49:29.203731Z FDA grants Fast Track Designation to Sobi's pacritinib for VEXAS syndrome https://allsci.com/news/venture-financing/encoded-therapeutics-funding-dravet-syndrome/ AllScien 2026-09-11T09:18:45.585390Z Encoded Therapeutics raises USD 275m to push ETX101 toward pivotal Dravet syndrome trial https://allsci.com/news/funding/fragile-x-syndrome-treatment-funding-connecta/ AllScien 2026-09-11T09:01:18.096516Z CONNECTA raises EUR 3.1m to advance TrkB modulator into mid-stage Fragile X trial https://allsci.com/news/funding/mrna-nasal-antiviral-funding-ethris-secures-eur/ AllScien 2026-09-11T08:49:59.014554Z Ethris secures EUR 30m to advance broad-spectrum nasal antiviral into Phase IIb trials https://allsci.com/news/debt-financing/cerenome-financing-cnside-secures-usd-20-million/ AllScien 2026-09-11T08:25:23.378839Z Cerenome secures USD 20m royalty-based financing to scale CNSide diagnostics platform https://allsci.com/news/licensing-and-partnerships/cd3-t-cell-engager-third-arc-bio-advances-first/ AllScien 2026-09-11T08:12:02.903711Z Third Arc Bio advances first masked CD3 TCE under expanded Adagene collaboration https://allsci.com/news/regulatory/fda-clinical-hold-opakalim-partial-on-biohavens/ AllScien 2026-09-10T17:50:09.630019Z FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track https://allsci.com/news/funding/neonc-funding-cns-cancer-raises-usd-15m-to/ AllScien 2026-09-10T17:39:26.601356Z NeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout https://allsci.com/news/clinical-trials/atogepant-menstrual-migraine-abbvies-meets/ AllScien 2026-09-10T15:45:20.115410Z AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial https://allsci.com/news/venture-financing/spinal-cord-injury-genetic-medicine-vianautis/ AllScien 2026-09-10T15:23:01.290558Z ViaNautis expands into spinal cord injury with SCI Ventures backing for polyNaut platform https://allsci.com/news/clinical-trials/ruvonoflast-phase-ii-trial-rezeras-cuts/ AllScien 2026-09-10T15:09:59.570699Z NodThera rebrands as Rezera as ruvonoflast meets Phase II endpoint, eyes Phase III in PAD https://allsci.com/news/research/quinacrine-cutaneous-lupus-treatment-mindera/ AllScien 2026-09-10T14:50:23.280930Z Mindera Health partners with UPenn to investigate quinacrine mechanism in lupus https://allsci.com/news/clinical-trials/istaroxime-cardiogenic-shock-trial-seismic/ AllScien 2026-09-10T10:45:11.062233Z Seismic launches global Phase III trial of istaroxime in cardiogenic shock https://allsci.com/news/grants/heart-failure-ai-system-updoc-receives-up-to-92/ AllScien 2026-09-10T10:35:28.951396Z UpDoc receives up to USD 9.2m from ARPA-H for autonomous heart failure AI system https://allsci.com/news/funding/a2m-osteoarthritis-clinical-trial-cytonics-raises/ AllScien 2026-09-10T10:27:14.260338Z Cytonics crowdfunds USD 4.8m to advance A2M biologic into Phase Ib/IIa osteoarthritis study https://allsci.com/news/development/focused-ultrasound-brain-drug-delivery-lotus/ AllScien 2026-09-10T10:20:09.456550Z Insightec spinout Lotus Neuro launches brain drug delivery platform https://allsci.com/news/clinical-trials/polycythemia-vera-treatment-disc-medicines/ AllScien 2026-09-10T10:14:14.629174Z Disc Medicine’s DISC-3405 reduces phlebotomy needs in Phase II polycythemia vera trial https://allsci.com/news/clinical-trials/ai-drug-phase-iii-ipf-trial-insilico-advances/ AllScien 2026-09-10T09:51:43.145571Z Insilico’s rentosertib becomes first AI-discovered drug to enter Phase III https://allsci.com/news/grants/heart-failure-ai-agent-tempus-secures-95-million/ AllScien 2026-09-10T09:46:08.210307Z Tempus wins USD 9.5m in ARPA-H funding to develop autonomous cardiology AI https://allsci.com/news/regulatory/enspryng-mogad-fda-approval-grants-priority/ AllScien 2026-09-10T09:33:07.227624Z Roche moves Enspryng toward first approved MOGAD therapy https://allsci.com/news/approvals/her2-mutated-lung-cancer-treatment-fda-grants/ AllScien 2026-09-10T09:11:19.843253Z Bayer’s Hyrnuo joins Boehringer’s Hernexeos in first-line HER2-mutant NSCLC https://allsci.com/news/research/prmt7-cd8-t-cell-mcgill-and-mount-sinai/ AllScien 2026-09-10T07:58:52.461711Z McGill and Mount Sinai researchers identify PRMT7 as suppressor of CD8+ T cell expansion